Advertisement

Severe Preoperative Symptoms Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection

  • Heather A. Lillemoe
  • Rebecca K. Marcus
  • Bradford J. Kim
  • Nisha Narula
  • Catherine H. Davis
  • Qiuling Shi
  • Xin Shelley Wang
  • Thomas A. AloiaEmail author
Hepatobiliary Tumors
  • 6 Downloads

Abstract

Background

Symptom burden, as measured by patient-reported outcome (PRO) metrics, may have prognostic value in various cancer populations, but remains underreported. The aim of this project was to determine the predictive impact of preoperative patient-reported symptom burden on readiness to return to intended oncologic therapy (RIOT) after oncologic liver resection.

Methods

Preoperative factors, including anthropometric analysis of sarcopenia, were collected for patients undergoing oncologic liver resection from 2015 to 2018. All patients reported their preoperative symptom burden using the MD Anderson Symptom Inventory, Gastrointestinal version (MDASI-GI). Time to RIOT readiness was compared using standard statistics.

Results

Preoperative symptom burden was measured in 107 consecutive patients; 52% had at least one moderate symptom score and 21% reported at least one severe score. Highest rated symptoms were fatigue, disturbed sleep, and distress. For patients reporting a severe preoperative symptom burden, the median time to RIOT readiness was 35 days (interquartile range [IQR] 28–42), compared with 21 days (IQR 21–28) for those without severe symptoms (p < 0.001). On multivariable analysis, severe preoperative symptom burden was independently associated with longer time to RIOT readiness (estimate +7.5 days, 95% confidence interval 2.6–12.3; p = 0.002).

Conclusions

Preoperative symptom burden has a substantial impact on time to RIOT readiness, leading to, on average, a 7-day delay in RIOT readiness compared with patients without severe preoperative symptoms. Identifying and targeting severe preoperative symptoms may hasten recovery and improve time to necessary adjuvant therapies.

Notes

Acknowledgment

The authors thank Brigitte M. Taylor (Department of Surgical Oncology, MD Anderson Cancer Center) for administrative assistance in the preparation of this manuscript.

Funding

Dr. Heather Lillemoe is supported by National Institutes of Health grant T32CA009599 and MD Anderson Cancer Center support Grant P30 CA016672. Dr. Xin Shelley Wang is supported by Grants from the US National Cancer Institute (R01 CA205146).

Supplementary material

10434_2019_7719_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
    Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107–14.CrossRefGoogle Scholar
  2. 2.
    Kim BJ, Caudle AS, Gottumukkala V, Aloia TA. The impact of postoperative complications on a timely return to intended oncologic therapy (RIOT): the role of enhanced recovery in the cancer journey. Int Anesthesiol Clin. 2016;54(4):e33–46.CrossRefGoogle Scholar
  3. 3.
    Day RW, Cleeland CS, Wang XS, et al. Patient-reported outcomes accurately measure the value of an enhanced recovery program in liver surgery. J Am Coll Surg. 2015;221(6):1023–30.e1-2.CrossRefGoogle Scholar
  4. 4.
    Yeo HL, O’Mahoney PR, Lachs M, et al. Surgical oncology outcomes in the aging US population. J Surg Res. 2016;205(1):11–8.CrossRefGoogle Scholar
  5. 5.
    Ruzzenente A, Conci S, Ciangherotti A, et al. Impact of age on short-term outcomes of liver surgery: lessons learned in 10-years’ experience in a tertiary referral hepato-pancreato-biliary center. Medicine (Baltimore). 2017;96(20):e6955.CrossRefGoogle Scholar
  6. 6.
    Cooper AB, Slack R, Fogelman D, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22(7):2416–23.CrossRefGoogle Scholar
  7. 7.
    Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13(7):439–46.CrossRefGoogle Scholar
  8. 8.
    Deyle S, Banz VM, Wagner M, et al. Estimation of physiologic ability and surgical stress score does not predict immediate outcome after pancreatic surgery. Pancreas. 2011;40(5):723–9.CrossRefGoogle Scholar
  9. 9.
    Valero V 3rd, Amini N, Spolverato G, et al. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015;19(2):272–81.CrossRefGoogle Scholar
  10. 10.
    Underwood PW, Cron DC, Terjimanian MN, Wang SC, Englesbe MJ, Waits SA. Sarcopenia and failure to rescue following liver transplantation. Clin Transplant. 2015;29(12):1076–80.CrossRefGoogle Scholar
  11. 11.
    Lodewick TM, van Nijnatten TJ, van Dam RM, et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB (Oxford). 2015;17(5):438–46.CrossRefGoogle Scholar
  12. 12.
    Rees JR, Rees M, McNair AG, et al. The prognostic value of patient-reported outcome data in patients with colorectal hepatic metastases who underwent surgery. Clin Colorectal Cancer. 2016;15(1):74–81.e71.CrossRefGoogle Scholar
  13. 13.
    Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.CrossRefGoogle Scholar
  14. 14.
    Lillemoe HA, Marcus RK, Kim BJ, Narula N, Davis CH, Aloia TA. Detours on the road to recovery: What factors delay readiness to return to intended oncologic therapy (riot) after liver resection for malignancy? J Gastrointest Surg.  https://doi.org/10.1007/s11605-019-04165-5. (Epub 26 Feb 2019).Google Scholar
  15. 15.
    Yeo W, Mo FKF, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006;17(7):1083–89.CrossRefGoogle Scholar
  16. 16.
    Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non—small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study. J Clin Oncol. 2005;23(28):6865–72.CrossRefGoogle Scholar
  17. 17.
    Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38(10):1351–7.CrossRefGoogle Scholar
  18. 18.
    Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2006;15(8):1297–306.CrossRefGoogle Scholar
  19. 19.
    Wang XS, Williams LA, Eng C, et al. Validation and application of a module of symptom inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010;116(8):2053–63.CrossRefGoogle Scholar
  20. 20.
    Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120(3):425–32.CrossRefGoogle Scholar
  21. 21.
    Shi Q, Mendoza TR, Dueck AC, et al. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017;158(6):1108–12.CrossRefGoogle Scholar
  22. 22.
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefGoogle Scholar
  23. 23.
    Couinaud C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver [in French]. Presse Med. 1954;62(33):709–12.Google Scholar
  24. 24.
    Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.CrossRefGoogle Scholar
  25. 25.
    Antonelli G, Gigante E, Iavarone M, et al. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United Eur Gastroenterol J. 2018;6(7):1039–48.CrossRefGoogle Scholar
  26. 26.
    Lodewick TM, Roeth AAJ, Olde Damink SWM, et al. Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. J Cachexia Sarcopenia Muscle. 2015;6(2):155–63.CrossRefGoogle Scholar
  27. 27.
    Dasgupta D, Smith AB, Hamilton-Burke W, et al. Quality of life after liver resection for hepatobiliary malignancies. Br J Surg. 2008;95(7):845–54.CrossRefGoogle Scholar
  28. 28.
    Martin RCG, Eid S, Scoggins CR, McMasters KM. Health-related quality of life: return to baseline after major and minor liver resection. Surgery. 2007;142(5):676–84.CrossRefGoogle Scholar
  29. 29.
    Banz VM, Inderbitzin D, Fankhauser R, Studer P, Candinas D. Long-term quality of life after hepatic resection: health is not simply the absence of disease. World J Surg. 2009;33(7):1473–80.CrossRefGoogle Scholar
  30. 30.
    Rees JR, Blazeby JM, Fayers P, et al. Patient-reported outcomes after hepatic resection of colorectal cancer metastases. J Clin Oncol. 2012;30(12):1364–70.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Heather A. Lillemoe
    • 1
  • Rebecca K. Marcus
    • 1
  • Bradford J. Kim
    • 1
  • Nisha Narula
    • 1
  • Catherine H. Davis
    • 1
  • Qiuling Shi
    • 2
  • Xin Shelley Wang
    • 2
  • Thomas A. Aloia
    • 1
    Email author
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Symptom ResearchThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations